SCHEMBL903622

SCHEMBL903622

COC(=O)[C@@H](NC(=O)OCc1ccccc1)C1CCOCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 3/20 0.50
CTSS P25774 3/20 0.50
CTSK P43235 3/20 0.50
CYP1A2 P05177 4/20 0.49
ALDH1A1 P00352 5/20 0.48
CYP2C9 P11712 4/20 0.48
CYP2C19 P33261 4/20 0.48
CYP3A4 P08684 4/20 0.48
TSHR P16473 4/20 0.48
POLB P06746 1/20 0.48
CYP2D6 P10635 1/20 0.48
ATM Q13315 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 1/20 0.47
LMNA P02545 1/20 0.47
KMT2A Q03164 1/20 0.47
MAPK1 P28482 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TRPM8 Q7Z2W7 1/20 0.47
ALOX15 P16050 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3369219 1.00 CTSL (0.50) CTSLCTSSCTSKCYP1A2ALDH1A1
SCHEMBL18730895 0.90 CTSK (0.45) CTSLCTSSCTSKCYP1A2ALDH1A1
SCHEMBL3374501 0.90 CTSK (0.49) CTSLCTSSCTSKCYP1A2ALDH1A1
SCHEMBL1162837 0.90 CTSK (0.49) CTSLCTSSCTSKCYP1A2ALDH1A1
SCHEMBL13308110 0.89 ATM (0.51) CTSLCTSSCTSKCYP1A2ALDH1A1
SCHEMBL29618020 0.89 ATM (0.51) CTSLCTSSCTSKCYP1A2ALDH1A1
SCHEMBL29618021 0.89 ATM (0.51) CTSLCTSSCTSKCYP1A2ALDH1A1
SCHEMBL20825664 0.88 EPHX1 (0.56) CTSLCTSSCTSKCYP1A2ALDH1A1
SCHEMBL620790 0.87 CYP1A2 (0.52) CTSLCTSSCTSKCYP1A2ALDH1A1
SCHEMBL620642 0.87 CYP1A2 (0.52) CTSLCTSSCTSKCYP1A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796705-B2 Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases MERCK SHARP & DOHME CORP. (US) 2017-10-24 US disclosed
US-20170008879-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. (US) 2017-01-12 US disclosed
EP-2545060-B1 FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME (US) 2015-11-25 EP disclosed
US-9040706-B2 Pyrrolidine inhibitors of IAP GENENTECH, INC. (US) 2015-05-26 US disclosed
US-9040706-B2 Pyrrolidine inhibitors of IAP GENENTECH, INC. (US) 2015-05-26 US disclosed
US-8980920-B2 Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C MERCK SHARP & DOHME CORP. (US) 2015-03-17 US disclosed
US-20150057246-A1 SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. 2015-02-26 US disclosed
US-20140378416-A1 SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. 2014-12-25 US disclosed
US-8907092-B2 Inhibitors of IAP GENENTECH, INC. (US) 2014-12-09 US disclosed
US-8907092-B2 Inhibitors of IAP GENENTECH, INC. (US) 2014-12-09 US disclosed
US-8063218-B2 Imidazopyridine inhibitors of IAP GENENTECH, INC. (US) 2011-11-22 US disclosed
US-20110223134-A1 FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME LLC 2011-09-15 US disclosed
US-20110218211-A1 AZAINDOLE INHIBITORS OF IAP GENENTECH, INC. (US) 2011-09-08 US disclosed
US-20110077265-A1 INHIBITORS OF IAP GENENTECH, INC. (US) 2011-03-31 US disclosed
US-20110046066-A1 INHIBITORS OF IAP GENENTECH, INC. (US) 2011-02-24 US disclosed
US-20100130539-A1 IMIDAZOPYRIDINE INHIBITORS OF IAP GENENTECH INC. (US) 2010-05-27 US disclosed
US-20090318409-A1 PYRROLIDINE INHIBITORS OF IAP GENENTECH, INC. (US) 2009-12-24 US disclosed
US-20090221630-A1 IAP INHIBITORS GENENTECH, INC. 2009-09-03 US disclosed
US-20090176822-A1 PYRROLIDINE INHIBITORS OF IAP GENENTECH, INC. (US) 2009-07-09 US disclosed
WO-2007106192-A2 INHIBITORS OF IAP GENENTECH, INC. (US) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221630-A1 IAP INHIBITORS XIAP, BIRC5, BIRC3 CTSL 534/4885CTSS 1000/4885CTSK 1063/4885
US-20090176822-A1 PYRROLIDINE INHIBITORS OF IAP BIRC5, XIAP, BIRC2 CTSL 860/4885CTSS 1651/4885CTSK 1703/4885
US-20150057246-A1 SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES HAVCR2, HBS1L, HBB CTSL 681/4885CTSS 1757/4885CTSK 2639/4885
US-20110046066-A1 INHIBITORS OF IAP BIRC5, XIAP, BIRC3 CTSL 876/4885CTSS 1884/4885CTSK 1714/4885
US-20170008879-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES ZC3HAV1, HAVCR2, ZC3HAV1L CTSL 930/4885CTSS 381/4885CTSK 672/4885
US-20110218211-A1 AZAINDOLE INHIBITORS OF IAP XIAP, BIRC5, API5 CTSL 1535/4885CTSS 2034/4885CTSK 1939/4885
US-20110223134-A1 FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES FOXM1, ZC3HAV1L, C1S CTSL 119/4885CTSS 389/4885CTSK 1046/4885
US-20140378416-A1 SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES ZC3HAV1L, HBS1L, HAVCR2 CTSL 138/4885CTSS 1174/4885CTSK 1950/4885
US-20100130539-A1 IMIDAZOPYRIDINE INHIBITORS OF IAP BIRC5, XIAP, BIRC3 CTSL 1080/4885CTSS 2404/4885CTSK 2294/4885
US-20090318409-A1 PYRROLIDINE INHIBITORS OF IAP BIRC5, XIAP, BIRC2 CTSL 860/4885CTSS 1651/4885CTSK 1703/4885
US-20110077265-A1 INHIBITORS OF IAP XIAP, BIRC5, BIRC2 CTSL 1490/4885CTSS 2271/4885CTSK 2243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.